2013
DOI: 10.1016/j.gie.2013.03.170
|View full text |Cite
|
Sign up to set email alerts
|

A novel ingestible electronic drug delivery and monitoring device

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
75
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 99 publications
(75 citation statements)
references
References 20 publications
0
75
0
Order By: Relevance
“…It can be programmed to release a drug either continuously or as a bolus by a miniaturized pump (Becker et al, 2014;van der Schaar et al, 2013). The system consists of a body and a cap (Figure 19).…”
Section: Telemetrymentioning
confidence: 99%
“…It can be programmed to release a drug either continuously or as a bolus by a miniaturized pump (Becker et al, 2014;van der Schaar et al, 2013). The system consists of a body and a cap (Figure 19).…”
Section: Telemetrymentioning
confidence: 99%
“…Thanks to recent advances in ingestible electronics, it is now possible to perform video capture 1 , electronically-controlled drug release 2 , pH, temperature, and pressure recording 3 , and heart rate and respiration monitoring 4 , all from within electronic pill-like capsules placed in the gastrointestinal (GI) tract. Recent progress in energy harvesting and wireless power transfer is offering new options to power these devices, but many are not well suited to ingestible capsules.…”
mentioning
confidence: 99%
“…The availability of a controllable Drug Delivery Systems (DDS) may reduce toxicity associated with systemic administration and prevent the formation of antibodies to drugs, particularly in the case of colon cancer or inflammatory bowel disease therapies [13]. These are two extremely common diseases, with colorectal cancer being the second leading cause of cancer-related deaths in USA [14], while Crohns disease and ulcerative colitis -both inflammatory bowel diseases -being diagnosed in 201 and 238 per 100,000 people in the USA, respectively.…”
Section: Clinical Motivation For Drug Delivery Systemsmentioning
confidence: 99%